当前位置： SCI文献检索 > International Journal of Clinical Pharmacy期刊下所有文献 > Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice.

Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice.

Abstract：

OBJECTIVE:In September 2007, the FDA issued an alert recommending that ceftriaxone and calcium-containing solutions should not be administered to any patient within 48 h of each other. Due to the widespread use of ceftriaxone, significant concern was expressed by the greater healthcare community about the warning, which the FDA eventually retracted in April of 2009. We sought to quantify the impact of the warning on healthcare institutions. SETTING:A survey was administered to the membership of the Society of Infectious Diseases Pharmacists to quantify perceived changes in ceftriaxone use among healthcare institutions across the United States. METHOD:A survey of Infectious Diseases experts was conducted. Participants were queried for hospital policies/drug use statistics during two times: immediately after the FDA warning and approximately 13 months post warning (preceding the FDA retraction). MAIN OUTCOME MEASURE:Related changes in formulary, drug-use policy, and the number of employee hours that were devoted to addressing the FDA warning were assessed. RESULTS:Ninety-four surveys representing 94 hospital systems were included in the analysis. Approximately half (n = 49, 52%) of respondent institutions enacted at least one drug-use policy change based on the warning; one institution removed ceftriaxone from a clinical protocol. Institutions' final interpretations of the warning differed slightly from initial understanding of the warning, and there was an overall minor decrease in the perceived use of ceftriaxone. The majority of those surveyed (n = 70, 74%) estimated that their respective institutions devoted between 1 and 49 employee hours to address the warning. CONCLUSION:Hospitals with ID pharmacists had minimal changes to ceftriaxone use after the 2007 FDA warning. Specialized pharmacists may be uniquely situated to help hospitals interpret global recommendations locally.

journal_name

Int J Clin Pharm

journal_title

International journal of clinical pharmacy

authors

Esterly JS,Steadman E,Scheetz MH

doi

10.1007/s11096-011-9503-4

subject

Has Abstract

pub_date

2011-06-01 00:00:00

pages

537-42

issue

eissn

2210-7703

issn

2210-7711

journal_volume

pub_type

杂志文章

在线工具

Impact of the FDA warning of potential ceftriaxone and calcium interactions on drug use policy in clinical practice.